Stock Ratings / Health Care / NDRA / forecast

IRIX (34) ITOC (35) NUWE (45) NXL (37) ⌘ Pro Terminal →

ENDRA Life Sciences Inc. (NDRA) 12-Month Stock Forecast & Price Target Cone

$4.88 +2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.90

ENDRA Life Sciences Inc. (NDRA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $7.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.90 (+0.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NDRA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY NDRA SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)

FRED Regime × Technicals: 48% of 52W Range • RSI-14 at 42 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$5.46-13.2% Next Q

Q2 (-2Q)

Grade C-$4.74+1.3% Next Q

Q3 (-1Q)

Grade C-$4.80+1.7% Next Q

Current

Grade D$4.88-5.6% Hist 90D α

Trajectory: C (56) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NDRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NDRA currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.44) and Max Pain ($5.12) forces dealer call-delta covering toward $7.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NDRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NDRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NDRA Position Size: $10,000

Shares at $4.88: 2049.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.63

$7,439

$-2,561 (-25.6%)

12M Consensus BaseTarget $4.66

$9,549

$-451 (-4.5%)

12M Bull Case BreakoutTarget $7.30

$14,959

+$4,959 (+49.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$5	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$7	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NDRA)

✓Walkthrough of NDRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NDRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.21%📐 HORIZONTAL RANGE

2026-10-30O $4.85H $4.88L $4.72C $4.88VOL 10.6K

RES: $6.82SUP: $4.29SMA50: $5.44SMA200: $4.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NDRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NDRA Butterfly Map → + Track NDRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NDRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NDRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NDRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NDRA)

Health Care Rank #396 of 1016 ⚔️ IRIX vs NDRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NDRA vs. IRIX, ITOC, NUWE, NXL)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ENDRA Life Sciences Inc. (NDRA) ranks #396 by composite RQD confidence (48/100, grade D) and #919 by equity capitalization ($7.3M). Within this direct 5-issuer industry benchmark cohort, NDRA leads on earnings valuation at N/A trailing P/E, while NDRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NDRA ACTIVE ENDRA Life Sciences Inc.	D	48/100	—	—	-35.0%	+2.95%	$7.3M	Benchmark Subject
IRIX IRIDEX Corporation	E	34/100	—	36.5%	-35.0%	-2.92%	$12.7M	/irix-vs-ndra →
ITOC iTonic Holdings Ltd (Class A)	D-	35/100	—	62.6%	-35.0%	-4.99%	$20.9M	/itoc-vs-ndra →
NUWE Nuwellis Inc.	D	45/100	—	62.0%	-35.0%	+2.12%	$2.3M	/nuwe-vs-ndra →
NXL Nexalin Technology Inc.	D-	37/100	—	79.7%	-35.0%	0.00%	$1.9M	/nxl-vs-ndra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681682

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.0M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+29.9% YoY). On the balance sheet, NDRA closed FY2025 with $3.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$7.0M	-$5.2M	-$5.2M	$3.9M	—
FY2024 (FY)	2024-12-31	$0	-$11.5M	-$7.4M	-$7.4M	$4.5M	—
FY2023 (FY)	2023-12-31	$0	-$10.1M	-$9.5M	-$9.5M	—	—

3. NDRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $4.88 (+2.95% 1D, market cap $7.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NDRA ranks #396 in composite RQD confidence.

How does NDRA compare to IRIX and ITOC in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and ITOC (iTonic Holdings Ltd (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NDRA?

Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $0 in revenue, -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NDRA trading relative to its 50-day, 200-day, and 52-week technical levels?

NDRA last traded at $4.88 (+2.95% on volume of 14,642 shares), positioning the stock -10.29% below its 50-day simple moving average ($5.44) and +1.46% above its 200-day simple moving average ($4.81). Across its 52-week range of $2.96 to $6.95, NDRA sits at the 48.1% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.27 to $5.49).

NDRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NDRA's 12-month stock price target?

ENDRA Life Sciences Inc. (NDRA) carries a 12-month consensus base price target of $4.66 (-4.5% from $4.88), with a bull-case target of $7.3 and a bear-case floor of $3.63.

Is NDRA stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NDRA D (Sell — SELL) with an RQD Confidence score of 48/100.

Direct Sub-Reports: NDRA RQD Cockpit NDRA 12M Forecast NDRA Earnings & Move NDRA Dividends & DRIP NDRA Insiders & 13F NDRA Whale Options NDRA Profit Sankey NDRA News & Why